New scan could spot prostate cancer spread better than current test

NCT ID NCT07635524

Not yet recruiting Diagnosis Sponsor: Hoag Memorial Hospital Presbyterian Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a new radioactive imaging agent, 61Cu-NU101, can detect prostate cancer spread as well as or better than the current standard, Pylarify. 34 men with confirmed prostate cancer and visible disease on a prior Pylarify scan will receive one dose of 61Cu-NU101 followed by PET/CT imaging. The study compares the two scans to see if the new agent finds more or different cancer spots.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 61Cu-NU101 (a radioactive imaging agent)
What this could lead to: If successful, this could provide a new, equally effective or better imaging option for detecting prostate cancer spread.
What could go wrong: This is a small, early-phase study (34 people) comparing two scans, not a treatment. It may not show a meaningful improvement over the current standard.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Neoplasm Metastasis prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Hoag Family Cancer Institute

Newport Beach, California, 92663, United States
Washington Univeristy School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.